Ad
Search
Generic filters
Filter by content type
Taxonomy terms

HOWL – Werewolf Therapeutics Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

1.25

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 16.5

Low: 9

High: 20

Total Analysts: 4

Company Profile

Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of cancer treatments. The Company is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. The Company’s product candidates include WTX-124, WTX-330 and WTX-613. The Company’s advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12). Its INDUKINE molecules for the treatment of solid tumors. The Company initiating a Phase I/Ib clinical trial for each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. WTX-613 is designed to have minimal activity in the periphery and is activated preferentially in the tumor microenvironment (TME) to release wild-type IFNα in the tumor and potentially stimulate an anti-tumor immune response.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses